Mechanisms for the prevention of vitamin e excess

Journal of Lipid Research

Volumn 54, Issue 9, 2013, Pages 2295-2306

  Traber, Maret G ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Alpha tocopherol; Lipoprotein metabolism; Xenobiotic metabolism

Indexed keywords

ALPHA CARBOXYETHYL HYDROXYCHROMAN; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 4F2; LIPOPROTEIN; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ANTIOXIDANT ACTIVITY; DETOXIFICATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; FAT INTAKE; GLUCURONIDATION; HUMAN; HYPERVITAMINOSIS; INTESTINE ABSORPTION; LIPID PEROXIDATION; LIPID TRANSPORT; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; LIVER FUNCTION; LIVER METABOLISM; LOW DRUG DOSE; METABOLIC REGULATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE LEVEL; VENOUS THROMBOEMBOLISM; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; XENOBIOTIC METABOLISM;

ALPHA-TOCOPHEROL; LIPOPROTEIN METABOLISM; XENOBIOTIC METABOLISM;

ABSORPTION; ALPHA-TOCOPHEROL; ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LIPOPROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VITAMIN E;

EID: 84878982364     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R032946     Document Type: Review

References (180)

1. Institute of Medicine. 2000. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academy Press, Washington, DC.
2. Vivekananthan, D. P., M. S. Penn, S. K. Sapp, A. Hsu, and E. J. Topol. 2003. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 361: 2017-2023.
3. Bjelakovic, G., D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud. 2007. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 297: 842-857.
4. Miller 3rd, E. R., R. Paston-Barriuso, D. Dalal, R. A. Riemersma, L. J. Appel, and E. Guallar. 2005. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142: 37-46.
5. Abner, E. L., F. A. Schmitt, M. S. Mendiondo, J. L. Marcum, and R. J. Kryscio. 2011. Vitamin E and all-cause mortality: a meta-analysis. Curr. Aging Sci. 4: 158-170.
6. Berry, D., J. K. Wathen, and M. Newell. 2009. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin. Trials. 6: 28-41.
7. Cheung, M. C., X. Q. Zhao, A. Chait, J. J. Albers, and B. G. Brown. 2001. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler. Thromb. Vasc. Biol. 21: 1320-1326.
8. Brown, B. G., X. Q. Zhao, A. Chait, L. D. Fisher, M. C. Cheung, J. S. Morse, A. A. Dowdy, E. K. Marino, E. L. Bolson, P. Alaupovic, et al. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345: 1583-1592.
9. Lonn, E., J. Bosch, S. Yusuf, P. Sheridan, J. Pogue, J. M. Arnold, C. Ross, A. Arnold, P. Sleight, J. Probstfield, et al. 2005. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 293: 1338-1347.
10. Traber, M. G., and J. Atkinson. 2007. Vitamin E, antioxidant and nothing more. Free Radic. Biol. Med. 43: 4-15.
11. Dussault, I., H. D. Yoo, M. Lin, E. Wang, M. Fan, A. K. Batta, G. Salen, S. K. Erickson, and B. M. Forman. 2003. Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. USA. 100: 833-838.
12. Evans, H. M., and K. S. Bishop. 1922. On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science. 56: 650-651.
13. Emerson, O. H., G. A. Emerson, A. Mohammad, and H. M. Evans. 1937. The chemistry of vitamin E. tocopherols from natural sources. J. Biol. Chem. 22: 99-107.
14. Leth, T., and H. Sondergaard. 1977. Biological activity of vitamin E compounds and natural materials by the resorption-gestation test, and chemical determination of the vitamin E activity in foods and feeds. J. Nutr. 107: 2236-2243.
15. Mene-Saffrane, L., and D. DellaPenna. 2010. Biosynthesis, regulation and functions of tocochromanols in plants. Plant Physiol. Biochem. 48: 301-309.
16. Bruno, R. S., S. W. Leonard, S-I. Park, Y. Zhao, and M. G. Traber. 2006. Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled - -tocopheryl acetate. Am. J. Clin. Nutr. 83: 299-304.
17. Jeanes, Y. M., W. L. Hall, S. Ellard, E. Lee, and J. K. Lodge. 2004. The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix. Br. J. Nutr. 92: 575-579.
18. Melia, A. T., S. G. Koss-Twardy, and J. Zhi. 1996. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J. Clin. Pharmacol. 36: 647-653.
19. Sokol, R. J., J. E. Heubi, S. Iannaccone, K. E. Bove, and W. F. Balistreri. 1983. Mechanism causing vitamin E deficiency during chronic childhood cholestasis. Gastroenterology. 85: 1172-1182.
20. Farrell, P. M., J. G. Bieri, J. F. Fratantoni, R. E. Wood, and P. A. di Sant'Agnese. 1977. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. J. Clin. Invest. 60: 233-241.
21. Elias, E., D. P. Muller, and J. Scott. 1981. Association of spinocerebellar disorders with cystic fibrosis or chronic childhood cholestasis and very low serum vitamin E. Lancet. 2: 1319-1321.
22. Sitrin, M. D., F. Lieberman, W. E. Jensen, A. Noronha, C. Milburn, and W. Addington. 1987. Vitamin E deficiency and neurologic disease in adults with cystic fibrosis. Ann. Intern. Med. 107: 51-54.
23. Papas, K., J. Kalbfleisch, and R. Mohon. 2007. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Dig. Dis. Sci. 52: 347-352.
24. Traber, M. G., C. A. Thellman, M. J. Rindler, and H. J. Kayden. 1988. Uptake of intact TPGS (d- - - tocopheryl polyethylene glycol 1000 succinate) a water miscible form of vitamin E by human cells in vitro. Am. J. Clin. Nutr. 48: 605-611.
25. Winklhofer-Roob, B. M., P. E. Tuchschmid, L. Molinari, and D. H. Shmerling. 1996. Response to a single oral dose of all-rac-alphatocopheryl acetate in patients with cystic fibrosis and in healthy individuals. Am. J. Clin. Nutr. 63: 717-721.
26. Winklhofer-Roob, B. M., M. A. van't Hof, and D. H. Shmerling. 1996. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alphatocopheryl acetate preparations. Am. J. Clin. Nutr. 63: 722-728.
27. Reboul, E., Z. Soayfane, A. Goncalves, M. Cantiello, R. Bott, M. Nauze, F. Terce, X. Collet, and C. Comera. 2012. Respective contributions of intestinal Niemann-Pick C1-like 1 and scavenger receptor class B type I to cholesterol and tocopherol uptake: in vivo v. in vitro studies. Br. J. Nutr. 107: 1296-1304.
28. Narushima, K., T. Takada, Y. Yamanashi, and H. Suzuki. 2008. Niemann-pick C1-like 1 mediates alpha-tocopherol transport. Mol. Pharmacol. 74: 42-49.
29. Reboul, E., A. Klein, F. Bietrix, B. Gleize, C. Malezet-Desmoulins, M. Schneider, A. Margotat, L. Lagrost, X. Collet, and P. Borel. 2006. Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte. J. Biol. Chem. 28: 4739-4745.
30. Rader, D. J., and H. B. Brewer, Jr. 1993. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA. 270: 865-869.
31. Mars, H., L. A. Lewis, A. L. Robertson, A. Butkus, and G. H. Williams. 1969. Familial hypobetalipoproteinemia. A genetic disorder of lipid metabolism with nervous system involvement. Am. J. Med. 46: 886-900.
32. Linton, M. F., R. V. Farese, Jr., and S. G. Young. 1993. Familial hypobetalipoproteinemia. J. Lipid Res. 34: 521-541.
33. Wetterau, J. R., L. P. Aggerbeck, M. E. Bouma, C. Eisenberg, A. Munck, M. Hermier, J. Schmitz, G. Gay, D. J. Rader, and R. E. Gregg. 1992. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 258: 999-1001.
34. Berriot-Varoqueaux, N., L. P. Aggerbeck, M. Samson-Bouma, and J. R. Wetterau. 2000. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu. Rev. Nutr. 20: 663-697.
35. Homer, V. M., P. M. George, S. du Toit, J. S. Davidson, and C. J. Wilson. 2005. Mental retardation and ataxia due to normotriglyceridemic hypobetalipoproteinemia. Ann. Neurol. 58: 160-163.
36. Malloy, M. J., J. P. Kane, D. A. Hardman, R. L. Hamilton, and K. B. Dalal. 1981. Normotriglyceridemic abetalipoproteinemia. absence of the B-100 apolipoprotein. J. Clin. Invest. 67: 1441-1450.
37. Traber, M. G., G. W. Burton, L. Hughes, K. U. Ingold, H. Hidaka, M. Malloy, J. Kane, J. Hyams, and H. J. Kayden. 1992. Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism. J. Lipid Res. 33: 1171-1182.
38. Anwar, K., J. Iqbal, and M. M. Hussain. 2007. Mechanisms involved in vitamin E transport by primary enterocytes and in vivo absorption. J. Lipid Res. 48: 2028-2038.
39. Kayden, H. J., L. J. Hatam, and M. G. Traber. 1983. The measurement of nanograms of tocopherol from needle aspiration biopsies of adipose tissue: normal and abetalipoproteinemic subjects. J. Lipid Res. 24: 652-656.
40. Traber, M. G., D. Rader, R. Acuff, H. B. Brewer, and H. J. Kayden. 1994. Discrimination between RRR - and all rac - - -tocopherols labeled with deuterium by patients with abetalipoproteinemia. Atherosclerosis. 108: 27-37.
41. Aguie, G. A., D. J. Rader, V. Clavery, M. G. Traber, G. Torpier, H. J. Kayden, J. C. Fruchart, H. B. Brewer, and G. Castro. 1995. Lipoproteins containing apolipoprotein B in abetalipoproteinemia and homozygous hypobetalipoproteinemia. Identification and characterization. Atherosclerosis. 118: 183-191.
42. Traber, M. G., and H. J. Kayden. 1989. Preferential incorporation of alpha-tocopherol vs gamma-tocopherol in human lipoproteins. Am. J. Clin. Nutr. 49: 517-526.
43. Traber, M. G., G. W. Burton, K. U. Ingold, and H. J. Kayden. 1990. RRR- and SRR-alpha-tocopherols are secreted without discrimination in human chylomicrons, but RRR-alpha-tocopherol is preferentially secreted in very low density lipoproteins. J. Lipid Res. 31: 675-685.
44. Traber, M. G., H. J. Kayden, J. B. Green, and M. H. Green. 1986. Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. Am. J. Clin. Nutr. 44: 914-923.
45. Tsuzuki, W., R. Yunoki, and H. Yoshimura. 2007. Intestinal epithelial cells absorb gamma-tocotrienol faster than alpha-tocopherol. Lipids. 42: 163-170.
46. Abuasal, B., P. W. Sylvester, and A. Kaddoumi. 2010. Intestinal absorption of gamma-tocotrienol is mediated by Niemann-Pick C1- like 1: in situ rat intestinal perfusion studies. Drug Metab. Dispos. 38: 939-945.
47. Abuasal, B. S., H. Qosa, P. W. Sylvester, and A. Kaddoumi. 2012. Comparison of the intestinal absorption and bioavailability of gamma-tocotrienol and alpha-tocopherol: in vitro, in situ and in vivo studies. Biopharm. Drug Dispos. 33: 246-256.
48. Abuasal, B. S., C. Lucas, B. Peyton, A. Alayoubi, S. Nazzal, P. W. Sylvester, and A. Kaddoumi. 2012. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases gammatocotrienol oral bioavailability. Lipids. 47: 461-469.
49. Novotny, J. A., J. G. Fadel, D. M. Holstege, H. C. Furr, and A. J. Clifford. 2012. This kinetic, bioavailability, and metabolism study of RRR-alpha-tocopherol in healthy adults suggests lower intake requirements than previous estimates. J. Nutr. 142: 2105-2111.
50. Porsgaard, T., and C. E. Hoy. 2000. Absorption by rats of tocopherols present in edible vegetable oils. Lipids. 35: 1073-1078.
51. Kelleher, J., and M. S. Losowsky. 1968. The absorption of vitamin E in man. Biochem. J. 110: 20P-21P.
52. Clifford, A. J., F. F. de Moura, C. C. Ho, J. C. Chuang, J. Follett, J. G. Fadel, and J. A. Novotny. 2006. A feasibility study quantifying in vivo human alpha-tocopherol metabolism. Am. J. Clin. Nutr. 84: 1430-1441.
53. Chuang, J. C., H. D. Matel, K. P. Nambiar, S. H. Kim, J. G. Fadel, D. M. Holstege, and A. J. Clifford. 2011. Quantitation of [5-14CH3]-(2R, 4'R, 8'R)-alpha-tocopherol in humans. J. Nutr. 141: 1482-1488.
54. Borel, P., N. Mekki, Y. Boirie, A. Partier, P. Grolier, M. C. Alexandre-Gouabau, B. Beaufrere, M. Armand, D. Lairon, and V. Azais-Braesco. 1997. Postprandial chylomicron and plasma vitamin E responses in healthy older subjects compared with younger ones. Eur. J. Clin. Invest. 27: 812-821.
55. Ouahchi, K., M. Arita, H. Kayden, F. Hentati, M. Ben Hamida, R. Sokol, H. Arai, K. Inoue, J. L. Mandel, and M. Koenig. 1995. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat. Genet. 9: 141-145.
56. Ben Hamida, C., N. Doerflinger, S. Belal, C. Linder, L. Reutenauer, C. Dib, G. Gyapay, A. Bignal, D. Le Paslier, D. Cohen, et al. 1993. Localization of Friedreich ataxia phenotype with selective vitamin E deficiency to chromosome 8q by homozygosity mapping. Nat. Genet. 5: 195-200.
57. Di Donato, I., S. Bianchi, and A. Federico. 2010. Ataxia with vitamin E deficiency: update of molecular diagnosis. Neurol. Sci. 31: 511-515.
58. Sato, Y., K. Hagiwara, H. Arai, and K. Inoue. 1991. Purification and characterization of the alpha-tocopherol transfer protein from rat liver. FEBS Lett. 288: 41-45.
59. Panagabko, C., S. Morley, S. Neely, H. Lei, D. Manor, and J. Atkinson. 2002. Expression and refolding of recombinant human alpha-tocopherol transfer protein capable of specific alpha-tocopherol binding. Protein Expr. Purif. 24: 395-403.
60. Traber, M. G., R. J. Sokol, G. W. Burton, K. U. Ingold, A. M. Papas, J. E. Huffaker, and H. J. Kayden. 1990. Impaired ability of patients with familial isolated vitamin E deficiency to incorporate alphatocopherol into lipoproteins secreted by the liver. J. Clin. Invest. 85: 397-407.
61. Traber, M. G., R. J. Sokol, A. Kohlschütter, T. Yokota, D. P. R. Muller, R. Dufour, and H. J. Kayden. 1993. Impaired discrimination between stereoisomers of a-tocopherol in patients with familial isolated vitamin E deficiency. J. Lipid Res. 34: 201-210.
62. Sato, Y., H. Arai, A. Miyata, S. Tokita, K. Yamamoto, T. Tanabe, and K. Inoue. 1993. Primary structure of alpha-tocopherol transfer protein from rat liver. Homology with cellular retinaldehydebinding protein. J. Biol. Chem. 268: 17705-17710.
63. Qian, J., J. Atkinson, and D. Manor. 2006. Biochemical consequences of heritable mutations in the alpha-tocopherol transfer protein. Biochemistry. 45: 8236-8242.
64. Morley, S., V. Cross, M. Cecchini, P. Nava, J. Atkinson, and D. Manor. 2006. Utility of a fluorescent vitamin E analogue as a probe for tocopherol transfer protein activity. Biochemistry. 45: 1075-1081.
65. Qian, J., S. Morley, K. Wilson, P. Nava, J. Atkinson, and D. Manor. 2005. Intracellular trafficking of vitamin E in hepatocytes: role of tocopherol transfer protein. J. Lipid Res. 46: 2072-2082.
66. Horiguchi, M., M. Arita, D. E. Kaempf-Rotzoll, M. Tsujimoto, K. Inoue, and H. Arai. 2003. pH-dependent translocation of alphatocopherol transfer protein (alpha-TTP) between hepatic cytosol and late endosomes. Genes Cells. 8: 789-800.
67. Thakur, V., S. Morley, and D. Manor. 2010. Hepatic alpha-tocopherol transfer protein: ligand-induced protection from proteasomal degradation. Biochemistry. 49: 9339-9344.
68. Morley, S., M. Cecchini, W. Zhang, A. Virgulti, N. Noy, J. Atkinson, and D. Manor. 2008. Mechanisms of ligand transfer by the hepatic tocopherol transfer protein. J. Biol. Chem. 283: 17797-17804.
69. Zhang, W. X., G. Frahm, S. Morley, D. Manor, and J. Atkinson. 2009. Effect of bilayer phospholipid composition and curvature on ligand transfer by the alpha-tocopherol transfer protein. Lipids. 44: 631-641.
70. Zhang, W. X., V. Thakur, A. Lomize, I. Pogozheva, C. Panagabko, M. Cecchini, M. Baptist, S. Morley, D. Manor, and J. Atkinson. 2011. The contribution of surface residues to membrane binding and ligand transfer by the alpha-tocopherol transfer protein (alpha-TTP). J. Mol. Biol. 405: 972-988.
71. Traber, M. G., G. W. Burton, and R. L. Hamilton. 2004. Vitamin E trafficking. Ann. N. Y. Acad. Sci. 1031: 1-12.
72. Shichiri, M., Y. Takanezawa, D. E. Rotzoll, Y. Yoshida, T. Kokubu, K. Ueda, H. Tamai, and H. Arai. 2010. ATP-Binding cassette transporter A1 is involved in hepatic alpha-tocopherol secretion. J. Nutr. Biochem. 21: 451-456.
73. Oram, J. F., A. M. Vaughan, and R. Stocker. 2001. ATP-binding cassette transporter A1 mediates cellular secretion of alpha-tocopherol. J. Biol. Chem. 276: 39898-39902.
74. Traber, M. G., L. L. Rudel, G. W. Burton, L. Hughes, K. U. Ingold, and H. J. Kayden. 1990. Nascent VLDL from liver perfusions of cynomolgus monkeys are preferentially enriched in RRR- compared with SRR- - tocopherol: studies using deuterated tocopherols. J. Lipid Res. 31: 687-694.
75. Arita, M., K. Nomura, H. Arai, and K. Inoue. 1997. alpha-Tocopherol transfer protein stimulates the secretion of alpha-tocopherol from a cultured liver cell line through a brefeldin A-insensitive pathway. Proc. Natl. Acad. Sci. USA. 94: 12437-12441.
76. Parks, E. J., D. Dare, K. B. Frazier, M. K. Hellerstein, R. A. Neese, E. Hughes, and M. G. Traber. 2000. Dependence of plasma - - tocopherol flux on very low-density triglyceride clearance in humans. Free Radic. Biol. Med. 29: 1151-1159.
77. Bowry, V. W., K. K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89: 10316-10320.
78. Pan, M., A. I. Cederbaum, Y. L. Zhang, H. N. Ginsberg, K. J. Williams, and E. A. Fisher. 2004. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Invest. 113: 1277-1287.
79. Andreo, U., J. Elkind, C. Blachford, A. I. Cederbaum, and E. A. Fisher. 2011. Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells. FASEB J. 25: 3554-3560.
80. Zannis, V. I., A. Chroni, and M. Krieger. 2006. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84: 276-294.
81. Rosenson, R. S., H. B. Brewer, Jr., W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X. C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125: 1905-1919.
82. Clevidence, B. A., and J. Lehmann. 1989. Alpha- and gammatocopherol levels in lipoproteins fractionated by affinity chromatography. Lipids. 24: 137-140.
83. Bjorneboe, A., G. E. Bjorneboe, and C. A. Drevon. 1987. Serum half-life, distribution, hepatic uptake and biliary excretion of alpha-tocopherol in rats. Biochim. Biophys. Acta. 921: 175-181.
84. Fairus, S., R. M. Nor, H. M. Cheng, and K. Sundram. 2006. Postprandial metabolic fate of tocotrienol-rich vitamin E differs significantly from that of alpha-tocopherol. Am. J. Clin. Nutr. 84: 835-842.
85. Fairus, S., R. M. Nor, H. M. Cheng, and K. Sundram. 2012. Alphatocotrienol is the most abundant tocotrienol isomer circulated in plasma and lipoproteins after postprandial tocotrienol-rich vitamin E supplementation. Nutr. J. 11: 5.
86. Hermann, W. J., Jr., K. Ward, and J. Faucett. 1979. The effect of tocopherol on high-density lipoprotein cholesterol. A clinical observation. Am. J. Clin. Pathol. 72: 848-852.
87. Aldred, S., T. Sozzi, I. Mudway, M. M. Grant, H. Neubert, F. J. Kelly, and H. R. Griffiths. 2006. Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. Proteomics. 6: 1695-1703.
88. Leonard, S. W., J. D. Joss, D. J. Mustacich, D. H. Blatt, Y. S. Lee, and M. G. Traber. 2007. Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins. Am. J. Health Syst. Pharm. 64: 2257-2266.
89. Hatam, L. J., and H. J. Kayden. 1981. The failure of - -tocopherol supplementation to alter the distribution of lipoprotein cholesterol in normal and hyperlipoproteinemic persons. Am. J. Clin. Pathol. 76: 122-126.
90. Oram, J. F., and R. M. Lawn. 2001. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 42: 1173-1179.
91. Reboul, E., D. Trompier, M. Moussa, A. Klein, J. F. Landrier, G. Chimini, and P. Borel. 2009. ATP-binding cassette transporter A1 is significantly involved in the intestinal absorption of alpha- and gamma-tocopherol but not in that of retinyl palmitate in mice. Am. J. Clin. Nutr. 89: 177-184.
92. Jiang, X. C., W. Jin, and M. Hussain. 2012. The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism. Nutr. Metab. (Lond.) 9: 75.
93. Klerkx, A. H., K. El Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S. Stroes, J. J. Kastelein, and J. A. Kuivenhoven. 2006. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler. Thromb. Vasc. Biol. 26: 706-715.
94. Schaefer, E. J., and B. F. Asztalos. 2006. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr. Opin. Lipidol. 17: 394-398.
95. Borel, P., M. Moussa, E. Reboul, B. Lyan, C. Defoort, S. Vincent- Baudry, M. Maillot, M. Gastaldi, M. Darmon, H. Portugal, et al. 2009. Human fasting plasma concentrations of vitamin E and carotenoids, and their association with genetic variants in apo C-III, cholesteryl ester transfer protein, hepatic lipase, intestinal fatty acid binding protein and microsomal triacylglycerol transfer protein. Br. J. Nutr. 101: 680-687.
96. Hacquebard, M., M. Vandenbranden, W. J. Malaisse, J. M. Ruysschaert, R. J. Deckelbaum, and Y. A. Carpentier. 2008. Vitamin E transfer from lipid emulsions to plasma lipoproteins: mediation by multiple mechanisms. Lipids. 43: 663-671.
97. Jiang, X. C., A. R. Tall, S. Qin, M. Lin, M. Schneider, F. Lalanne, V. Deckert, C. Desrumaux, A. Athias, J. L. Witztum, et al. 2002. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J. Biol. Chem. 277: 31850-31856.
98. Desrumaux, C., V. Deckert, S. Lemaire-Ewing, C. Mossiat, A. Athias, D. Vandroux, L. Dumont, S. Monier, J. P. Pais de Barros, A. Klein, et al. 2010. Plasma phospholipid transfer protein defi- ciency in mice is associated with a reduced thrombotic response to acute intravascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 30: 2452-2457.
99. Panagabko, C., S. Morley, M. Hernandez, P. Cassolato, H. Gordon, R. Parsons, D. Manor, and J. Atkinson. 2003. Ligand specificity in the CRAL-TRIO protein family. Biochemistry. 42: 6467-6474.
100. Shibata, N., M. Arita, Y. Misaki, N. Dohmae, K. Takio, T. Ono, K. Inoue, and H. Arai. 2001. Supernatant protein factor, which stimulates the conversion of squalene to lanosterol, is a cytosolic squalene transfer protein and enhances cholesterol biosynthesis. Proc. Natl. Acad. Sci. USA. 98: 2244-2249.
101. Shibata, N., K. Jishage, M. Arita, M. Watanabe, Y. Kawase, K. Nishikawa, Y. Natori, H. Inoue, H. Shimano, N. Yamada, et al. 2006. Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis. FASEB J. 20: 2642-2644.
102. Mariotti, C., C. Gellera, M. Rimoldi, R. Mineri, G. Uziel, G. Zorzi, D. Pareyson, G. Piccolo, D. Gambi, S. Piacentini, et al. 2004. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol. Sci. 25: 130-137.
103. Thurnham, D. I., J. A. Davies, B. J. Crump, R. D. Situnayake, and M. Davis. 1986. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann. Clin. Biochem. 23: 514-520.
104. Kayden, H. J. 1983. Tocopherol content of adipose tissue from vitamin E deficient humans. In Biology of Vitamin E. R. Porter and J. Whelan, editors. Pittman Books, London. 70-91.
105. Sokol, R. J., J. E. Heubi, S. T. Iannaccone, K. E. Bove, and W. F. Balistreri. 1984. Vitamin E deficiency with normal serum vitamin E concentrations in children with chronic cholestasis. N. Engl. J. Med. 310: 1209-1212.
106. Zhao, Y., M. J. Lee, C. Cheung, J. H. Ju, Y. K. Chen, B. Liu, L. Q. Hu, and C. S. Yang. 2010. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J. Agric. Food Chem. 58: 4844-4852.
107. Brigelius-Flohé, R., and M. G. Traber. 1999. Vitamin E: function and metabolism. FASEB J. 13: 1145-1155.
108. Eisengart, A., A. T. Milhorat, E. J. Simon, and L. Sundheim. 1956. The metabolism of vitamin E. II. Purification and characterization of urinary metabolites of alpha-tocopherol. J. Biol. Chem. 221: 807-817.
109. Schultz, M., M. Leist, M. Petrzika, B. Gassmann, and R. Brigelius- Flohé. 1995. Novel urinary metabolite of alpha-tocopherol, 2,5,7,8- tetramethyl-2(2'-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? Am. J. Clin. Nutr. 62 ( suppl. ): 1527S-1534S.
110. Li, Y. J., S. C. Luo, Y. J. Lee, F. J. Lin, C. C. Cheng, Y. S. Wein, Y. H. Kuo, and C. J. Huang. 2008. Isolation and identification of alpha-CEHC sulfate in rat urine and an improved method for the determination of conjugated alpha-CEHC. J. Agric. Food Chem. 56: 11105-11113.
111. Sharma, G., D. Muller, S. O'Riordan, S. Bryan, P. Hindmarsh, M. Dattani, and K. Mills. 2010. A novel method for the direct measurement of urinary conjugated metabolites of alpha-tocopherol and its use in diabetes. Mol. Nutr. Food Res. 54: 599-600.
112. Traber, M. G., A. Elsner, and R. Brigelius-Flohe. 1998. Synthetic as compared with natural vitamin E is preferentially excreted as alpha-CEHC in human urine: studies using deuterated alphatocopheryl acetates. FEBS Lett. 437: 145-148.
113. Swanson, J. E., R. N. Ben, G. W. Burton, and R. S. Parker. 1999. Urinary excretion of 2,7, 8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman is a major route of elimination of gamma-tocopherol in humans. J. Lipid Res. 40: 665-671.
114. Birringer, M., P. Pfluger, D. Kluth, N. Landes, and R. Brigelius- Flohe. 2002. Identities and differences in the metabolism of tocotrienols and tocopherols in HepG2 cells. J. Nutr. 132: 3113-3118.
115. Leonard, S. W., E. Paterson, J. K. Atkinson, R. Ramakrishnan, C. E. Cross, and M. G. Traber. 2005. Studies in humans using deuterium- labeled - - and - -tocopherol demonstrate faster plasma - - tocopherol disappearance and greater - -metabolite production. Free Radic. Biol. Med. 38: 857-866.
116. Freiser, H., and Q. Jiang. 2009. Gamma-tocotrienol and gammatocopherol are primarily metabolized to conjugated 2-(betacarboxyethyl)- 6-hydroxy-2,7,8-trimethylchroman and sulfated long-chain carboxychromanols in rats. J. Nutr. 139: 884-889.
117. Patel, V., S. Khanna, S. Roy, O. Ezziddin, and C. K. Sen. 2006. Natural vitamin E alpha-tocotrienol: retention in vital organs in response to long-term oral supplementation and withdrawal. Free Radic. Res. 40: 763-771.
118. Uchida, T., C. Abe, S. Nomura, T. Ichikawa, and S. Ikeda. 2012. Tissue distribution of alpha- and gamma-tocotrienol and gammatocopherol in rats and interference with their accumulation by alpha-tocopherol. Lipids. 47: 129-139.
119. Uchida, T., S. Nomura, T. Ichikawa, C. Abe, and S. Ikeda. 2011. Tissue distribution of vitamin E metabolites in rats after oral administration of tocopherol or tocotrienol. J. Nutr. Sci. Vitaminol. (Tokyo). 57: 326-332.
120. Yap, S. P., K. H. Yuen, and J. W. Wong. 2001. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J. Pharm. Pharmacol. 53: 67-71.
121. Sontag, T. J., and R. S. Parker. 2002. Cytochrome P450 omegahydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status. J. Biol. Chem. 277: 25290-25296.
122. Sontag, T. J., and R. S. Parker. 2007. Influence of major structural features of tocopherols and tocotrienols on their omega-oxidation by tocopherol-omega-hydroxylase. J. Lipid Res. 48: 1090-1098.
123. Ohnmacht, S., P. Nava, R. West, R. Parker, and J. Atkinson. 2008. Inhibition of oxidative metabolism of tocopherols with omega- N-heterocyclic derivatives of vitamin E. Bioorg. Med. Chem. 16: 7631-7638.
124. Bardowell, S. A., D. E. Stec, and R. S. Parker. 2010. Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}- hydroxylase specific activity. J. Nutr. 140: 1901-1906.
125. Major, J. M., K. Yu, W. Wheeler, H. Zhang, M. C. Cornelis, M. E. Wright, M. Yeager, K. Snyder, S. J. Weinstein, A. Mondul, et al. 2011. Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum. Mol. Genet. 20: 3876-3883.
126. Major, J. M., K. Yu, C. C. Chung, S. J. Weinstein, M. Yeager, W. Wheeler, K. Snyder, M. E. Wright, J. Virtamo, S. Chanock, et al. 2012. Genome-wide association study identifies three common variants associated with serologic response to vitamin E supplementation in men. J. Nutr. 142: 866-871.
127. Bardowell, S. A., X. Ding, and R. S. Parker. 2012. Disruption of P450-mediated vitamin E hydroxylase activities alters vitamin E status in tocopherol supplemented mice and reveals extra-hepatic vitamin E metabolism. J Lipid Res. 53: 2667-2676.
128. Bardowell, S. A., F. Duan, D. Manor, J. E. Swanson, and R. S. Parker. 2012. Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism. J. Biol. Chem. 287: 26077-26086.
129. Birringer, M., D. Drogan, and R. Brigelius-Flohe. 2001. Tocopherols are metabolized in HepG2 cells by side chain omega-oxidation and consecutive beta-oxidation. Free Radic. Biol. Med. 31: 226-232.
130. Parker, R. S., T. J. Sontag, and J. E. Swanson. 2000. Cytochrome P4503A-dependent metabolism of tocopherols and inhibition by sesamin. Biochem. Biophys. Res. Commun. 277: 531-534.
131. Ikeda, S., T. Tohyama, and K. Yamashita. 2002. Dietary sesame seed and its lignans inhibit 2,7,8-trimethyl-2(2'-carboxyethyl)-6- hydroxychroman excretion into urine of rats fed gamma-tocopherol. J. Nutr. 132: 961-966.
132. Kluth, D., N. Landes, P. Pfluger, K. Muller-Schmehl, K. Weiss, C. Bumke-Vogt, M. Ristow, and R. Brigelius-Flohe. 2005. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma- tocotrienol in mice. Free Radic. Biol. Med. 38: 507-514.
133. Traber, M. G., E. M. Labut, S. W. Leonard, and K. M. Lebold. 2011. alpha-Tocopherol injections in rats up-regulate hepatic ABC transporters, but not cytochrome P450 enzymes. Free Radic. Biol. Med. 51: 2031-2040.
134. Li, Y. J., and H. M. Shaw. 2007. Pregnenolone and dexamethasone, modulators of cytochrome P450-3A, not increase but reduce urinary alpha-CEHC excretion in rats. Biofactors. 31: 67-76.
135. Johnson, C. H., O. Slanar, K. W. Krausz, D. W. Kang, A. D. Patterson, J. H. Kim, H. Luecke, F. J. Gonzalez, and J. R. Idle. 2012. Novel metabolites and roles for alpha-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics. Am. J. Clin. Nutr. 96: 818-830.
136. Mustacich, D. J., K. Gohil, R. S. Bruno, M. Yan, S. W. Leonard, E. Ho, C. E. Cross, and M. G. Traber. 2009. Alpha-tocopherol modulates genes involved in hepatic xenobiotic pathways in mice. J. Nutr. Biochem. 20: 469-476.
137. Traber, M. G., L. K. Siddens, S. W. Leonard, B. Schock, K. Gohil, S. K. Krueger, C. E. Cross, and D. E. Williams. 2005. a-Tocopherol modulates Cyp3a expression, increases g-CEHC production and limits tissue g-tocopherol accumulation in mice fed high gtocopherol diets. Free Radic. Biol. Med. 38: 773-785.
138. Clarke, M. W., J. R. Burnett, J. H. Wu, J. M. Hodgson, T. Ledowski, I. B. Puddey, and K. D. Croft. 2009. Vitamin E supplementation and hepatic drug metabolism in humans. J. Cardiovasc. Pharmacol. 54: 491-496.
139. Werba, J. P., V. Cavalca, F. Veglia, P. Massironi, M. De Franceschi, L. Zingaro, and E. Tremoli. 2007. A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 193: 229-233.
140. Hsu, M. H., U. Savas, K. J. Griffin, and E. F. Johnson. 2007. Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab. Rev. 39: 515-538.
141. McDonald, M. G., M. J. Rieder, M. Nakano, C. K. Hsia, and A. E. Rettie. 2009. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75: 1337-1346.
142. Caldwell, M. D., T. Awad, J. A. Johnson, B. F. Gage, M. Falkowski, P. Gardina, J. Hubbard, Y. Turpaz, T. Y. Langaee, C. Eby, et al. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood. 111: 4106-4112.
143. Lasker, J. M., W. B. Chen, I. Wolf, B. P. Bloswick, P. D. Wilson, and P. K. Powell. 2000. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of CYP4F2 and CYP4A11. J. Biol. Chem. 275: 4118-4126.
144. Hardwick, J. P. 2008. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol. 75: 2263-2275.
145. Kikuta, Y., E. Kusunose, and M. Kusunose. 2000. Characterization of human liver leukotriene B(4) omega-hydroxylase P450 (CYP4F2). J. Biochem. 127: 1047-1052.
146. Kalsotra, A., and H. W. Strobel. 2006. Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol. Ther. 112: 589-611.
147. Munshi, A., V. Sharma, S. Kaul, A. Al-Hazzani, A. A. Alshatwi, G. Shafi, R. Koppula, S. B. Mallemoggala, and A. Jyothy. 2012. Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol. Biol. Rep. 39: 1677-1682.
148. Ding, H., G. Cui, L. Zhang, Y. Xu, X. Bao, Y. Tu, B. Wu, Q. Wang, R. Hui, W. Wang, et al. 2010. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet. Genomics. 20: 187-194.
149. Deng, S., G. Zhu, F. Liu, H. Zhang, X. Qin, L. Li, and H. Zhiyi. 2010. CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog. Neuropsychopharmacol. Biol. Psychiatry. 34: 664-668.
150. Liu, X., J. Wu, H. Liu, G. Lai, and Y. Zhao. 2012. Disturbed ratio of renal 20-HETE/EETs is involved in androgen-induced hypertension in cytochrome P450 4F2 transgenic mice. Gene. 505: 352-359.
151. Fava, C., M. Montagnana, E. Danese, M. Sjogren, P. Almgren, G. C. Guidi, B. Hedblad, G. Engstrom, P. Minuz, and O. Melander. 2012. The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes. Prostaglandins Other Lipid Mediat. 98: 31-36.
152. Liu, H., Y. Zhao, D. Nie, J. Shi, L. Fu, Y. Li, D. Yu, and J. Lu. 2008.
153. Jiang, Q., H. Freiser, K. V. Wood, and X. Yin. 2007. Identification and quantitation of novel vitamin E metabolites, sulfated longchain carboxychromanols, in human A549 cells and in rats. J. Lipid Res. 48: 1221-1230.
154. Freiser, H., and Q. Jiang. 2009. Optimization of the enzymatic hydrolysis and analysis of plasma conjugated gamma-CEHC and sulfated long-chain carboxychromanols, metabolites of vitamin E. Anal. Biochem. 388: 260-265.
155. Mustacich, D. J., S. W. Leonard, N. K. Patel, and M. G. Traber. 2010. Alpha-tocopherol beta-oxidation localized to rat liver mitochondria. Free Radic. Biol. Med. 48: 73-81.
156. Pope, S. A., G. E. Burtin, P. T. Clayton, D. J. Madge, and D. P. Muller. 2002. Synthesis and analysis of conjugates of the major vitamin E metabolite, alpha-CEHC. Free Radic. Biol. Med. 33: 807-817.
157. Cho, J. Y., D. W. Kang, X. Ma, S. H. Ahn, K. W. Krausz, H. Luecke, J. R. Idle, and F. J. Gonzalez. 2009. Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J. Lipid Res. 50: 924-937.
158. Hashiguchi, T., K. Kurogi, Y. Sakakibara, M. Yamasaki, K. Nishiyama, S. Yasuda, M. C. Liu, and M. Suiko. 2011. Enzymatic sulfation of tocopherols and tocopherol metabolites by human cytosolic sulfotransferases. Biosci. Biotechnol. Biochem. 75: 1951-1956.
159. Mustacich, D. J., S. W. Leonard, M. W. Devereaux, R. J. Sokol, and M. G. Traber. 2006. Alpha-tocopherol regulation of hepatic cytochrome P450s and ABC transporters in rats. Free Radic. Biol. Med. 41: 1069-1078.
160. Mustacich, D. J., J. Shields, R. A. Horton, M. K. Brown, and D. J. Reed. 1998. Biliary secretion of alpha-tocopherol and the role of the mdr2 P-glycoprotein in rats and mice. Arch. Biochem. Biophys. 350: 183-192.
161. Radosavac, D., P. Graf, M. C. Polidori, H. Sies, and W. Stahl. 2002. Tocopherol metabolites 2, 5, 7, 8-tetramethyl-2-(2'-carboxyethyl)- 6-hydroxychroman (alpha-CEHC) and 2, 7, 8-trimethyl-2-(2'- carboxyethyl)-6- hydroxychroman (gamma-CEHC) in human serum after a single dose of natural vitamin E. Eur. J. Nutr. 41: 119-124.
162. Bruno, R. S., S. W. Leonard, J. Li, T. M. Bray, and M. G. Traber. 2005. Lower plasma alpha-carboxyethyl-hydroxychroman after deuterium-labeled alpha-tocopherol supplementation suggests decreased vitamin E metabolism in smokers. Am. J. Clin. Nutr. 81: 1052-1059.
163. Morinobu, T., S. Yoshikawa, K. Hamamura, and H. Tamai. 2003. Measurement of vitamin E metabolites by high-performance liquid chromatography during high-dose administration of alphatocopherol. Eur. J. Clin. Nutr. 57: 410-414.
164. Imai, E., T. Tsuji, M. Sano, T. Fukuwatari, and K. Shibata. 2011. Association between 24 hour urinary alpha-tocopherol catabolite, 2,5,7,8-tetramethyl-2(2'-carboxyethyl)-6-hydroxychroman (alpha- CEHC) and alpha-tocopherol intake in intervention and crosssectional studies. Asia Pac. J. Clin. Nutr. 20: 507-513.
165. Lebold, K. M., A. Ang, M. G. Traber, and L. Arab. 2012. Urinary alpha-carboxyethyl hydroxychroman can be used as a predictor of alpha-tocopherol adequacy, as demonstrated in the Energetics Study. Am. J. Clin. Nutr. 96: 801-809.
166. Glynn, R. J., P. M. Ridker, S. Z. Goldhaber, R. Y. Zee, and J. E. Buring. 2007. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 116: 1497-1503.
167. Harrington, D. J., R. Soper, C. Edwards, G. F. Savidge, S. J. Hodges, and M. J. Shearer. 2005. Determination of the urinary aglycone metabolites of vitamin K by HPLC with redox-mode electrochemical detection. J. Lipid Res. 46: 1053-1060.
168. Nakagawa, K., Y. Hirota, N. Sawada, N. Yuge, M. Watanabe, Y. Uchino, N. Okuda, Y. Shimomura, Y. Suhara, and T. Okano. 2010. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature. 468: 117-121.
169. Okano, T., Y. Shimomura, M. Yamane, Y. Suhara, M. Kamao, M. Sugiura, and K. Nakagawa. 2008. Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. J. Biol. Chem. 283: 11270-11279.
170. Tovar, A., C. K. Ameho, J. B. Blumberg, J. W. Peterson, D. Smith, and S. L. Booth. 2006. Extrahepatic tissue concentrations of vitamin K are lower in rats fed a high vitamin E diet. Nutrition & Metabolism. 3: 29.
171. Farley, S. M., S. W. Leonard, E. M. Labut, H. F. Raines, D. J. Card, D. J. Harrington, D. J. Mustacich, and M. G. Traber. 2012. Vitamin E decreases extra-hepatic menaquinone-4 concentrations in rats fed menadione or phylloquinone. Mol. Nutr. Food Res. 56: 912-922.
172. Booth, S. L., I. Golly, J. M. Sacheck, R. Roubenoff, G. E. Dallal, K. Hamada, and J. B. Blumberg. 2004. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am. J. Clin. Nutr. 80: 143-148.
173. Ulatowski, L., C. Dreussi, N. Noy, J. Barnholtz-Sloan, E. Klein, and D. Manor. 2012. Expression of the alpha-tocopherol transfer protein gene is regulated by oxidative stress and common singlenucleotide polymorphisms. Free Radic. Biol. Med. 53: 2318-2326.
174. Dimitrov, N. V., C. Meyer, D. Gilliland, M. Ruppenthal, W. Chenoweth, and W. Malone. 1991. Plasma tocopherol concentrations in response to supplemental vitamin E. Am. J. Clin. Nutr. 53: 723-729.
175. Fuller, C. J., M. Chandalia, A. Garg, S. M. Grundy, and I. Jialal. 1996. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Am. J. Clin. Nutr. 63: 753-759.
176. Smith, K. S., C. L. Lee, J. W. Ridlington, S. W. Leonard, S. Devaraj, and M. G. Traber. 2003. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids. 38: 813-819.
177. Mustacich, D. J., A. T. Vo, V. D. Elias, K. Payne, L. Sullivan, S. W. Leonard, and M. G. Traber. 2007. Regulatory mechanisms to control tissue alpha-tocopherol. Free Radic. Biol. Med. 43: 610-618.
178. Burton, G. W., and K. U. Ingold. 1981. Autoxidation of biological molecules. I. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. J. Am. Chem. Soc. 103: 6472-6477.
179. Buettner, G. R. 1993. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300: 535-543.
180. Wang, X., B. Thomas, R. Sachdeva, L. Arterburn, L. Frye, P. G. Hatcher, D. G. Cornwell, and J. Ma. 2006. Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. Proc. Natl. Acad. Sci. USA. 103: 3604-3609.